Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central anxious system, conolidine modulates alternate molecular targets. A Science Developments research observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://riverkcnhg.weblogco.com/38055381/the-2-minute-rule-for-conolidin-to-replace-traditional-painkillers